Datapoint: BMS Scores New NSCLC Nod for Opdivo

The FDA on March 4 approved Bristol Myers Squibb’s Opdivo for the treatment of resectable non-small cell lung cancer (NSCLC) before surgery in the neoadjuvant setting in conjunction with platinum-doublet chemotherapy. The lightning-fast nod came within days of the agency’s priority review acceptance. As a systemic therapy for NSCLC, Opdivo holds covered or better status for 67% of all insured lives under the pharmacy benefit. 88% of all insured lives have covered or better access to Opdivo under the medical benefit.

SOURCE: MMIT Analytics, as of 3/9/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 22

Datapoint: Highmark Launching New Primary Care Initiative in Pittsburgh

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Novartis Asks FDA to Stave Off Early Entresto Copies

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 20

Datapoint: Oregon Adds Mobile Crisis Intervention to Medicaid Program

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today